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Abstract
Background: We investigated the determinants of sputum culture non-conversion following intensive phase of
treatment, and assessed the effects on the outcome among patients treated for a first episode of smear positive
tuberculosis (TB).
Methods: This was a prospective cohort study spanning October 2009 to May 2012, among patients treated for a
first episode of smear positive pulmonary tuberculosis in the Chest service of the Yaounde Jamot Hospital,
Cameroon. Logistic regressions models were used to relate baseline characteristics with non-conversion of sputum
cultures after the intensive phase of treatment.
Results: A total of 953 patients were admitted to the service during the study period, including 97 (10.2%) who
had a positive sputum smear at the end of the intensive phase of anti-tuberculosis treatment. Eighty-six patients
with persistent of smear positive sputa at the end of intensive phase of TB treatment were included, among whom
46 (53%) had positive sputum culture for Mycobacterium tuberculosis (C+). The absence of haemoptysis [adjusted odd
ratio 4.65 (95% confidence intervals: 1.14-18.95)] and current smoking [7.26 (1.59-33.23)] were the main determinants of
sputum culture non-conversion. Of the 46C + patients, 7 (15%) were resistant to at least one anti-tuberculosis drug.
Treatment failure rate was 28% among C + patients and 8% among C– patients (p = 0.023). The sensitivity and specificity
were 78.6% and 55.4% for culture non-conversion after intensive treatment, in predicting anti-TB treatment failure.
Conclusions: Failure rate is high among patients with positive sputum culture after intensive treatment, even in the
absence of multi-drug resistant bacilli. Treatment should be closely monitored in these patients and susceptibility to anti-
tuberculosis drugs tested in the presence of persistent positive smears following the intensive phase of treatment.
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Background
Tuberculosis (TB), despite the existing prevention and
control strategies remains a major public health problem.
In the year 2011 alone for example, 8.7 million new cases
of the disease were declared around the world, with a large
proportion of these occurring in developing countries [1].
In developing countries, insufficient resources are a deter-
rent to routine testing of the susceptibility of Mycobacter-
ium tuberculosis (M. tuberculosis) to antituberculosis drugs
prior to the treatment. In this context, direct sputum
examination for the presence of acid-fast bacilli (AFB) is
routinely used both to assess the contagiosity and to pre-
dict the outcome of care during the treatment of patients
with smear positive pulmonary tuberculosis (SPPTB) [2,3].
A negative sputum smear on direct sputum examination
at the end of the intensive phase of treatment is equally
used as criteria for the transition to the continuation
phase [2,3]. About 5 to 30% of patients with a first episode
of SPPTB according to some reports remain positive after
two months of treatment. A variable proportion of these
patients still have viable M. tuberculosis and as such con-
tinue to contribute to the spread of the disease [4]. It also
appears that the course of the disease in such patients is
* Correspondence: pefura2002@yahoo.fr
1Department of Internal Medicine and Subspecialties, Faculty of Medicine
and Biomedical Sciences, University of Yaounde I, Yaounde, Cameroon
2Pneumology service, Yaounde Jamot Hospital, Yaounde, Cameroon
Full list of author information is available at the end of the article
© 2014 Pefura-Yone et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly credited.
Pefura-Yone et al. BMC Infectious Diseases 2014, 14:138
http://www.biomedcentral.com/1471-2334/14/138
less favourable with high rates of treatment failure and
treatment discontinuation [5,6].
The relationship of positive smear with culture conver-
sion for M. tuberculosis at the completion of the inten-
sive phase of antituberculosis treatment as well as its
impact if any, on the outcome of care have in general
have been less investigated. In a study by Su et al. [7] the
non-use of directly observed treatment (DOT) and re-
sistance to rifampicin were reported to be the main fac-
tors associated with non-conversion of sputum culture
at the end of intensive phase of antituberculosis treat-
ment in Taiwan. The aim of this study was to determine
the frequency and identify factors associated with non-
conversion of sputum culture for M. tuberculosis as well
as assess its impact on the outcome of patients treated
for a first episode of SPPTB with persistent sputum smear




The study was conducted in Unit A of the Chest service of
the Yaounde Jamot Hospital (YJH), the reference hospital
for respiratory diseases for the capital city of Cameroon
(Yaounde) and surrounding areas. In this service, the diag-
nosis of SPPTB is made on the basis of a suggestive clinical
history and the presence of AFB on at least one of two
sputum samples submitted on two consecutive days by
the patient for microscopic examination, after staining
by the auramine technique [8]. Cultures for mycobac-
teria are hardly ever done because of costs.
All patients with a first episode of SPPTB are hospital-
ized during the intensive phase of treatment which lasts
for two months. The total duration of treatment is six
months. It consists of a two month intensive phase of
daily rifampicin (R), isoniazid (H), pyrazinamide (Z) and
ethambutol (E), followed by a four month continuation
phase of daily R and H on outpatient basis. Treatment in
the intensive phase is administered under direct supervi-
sion of the health personnel while compliance to treatment
during the continuation phase is assessed by monthly re-
turn for drug collection.
During the six month treatment period, the patients’
sputum is checked thrice for the presence or absence of
AFB by direct microscopic examination. This is done at
the end of the two month intensive phase and at the end
of fifth and sixth month of treatment. In patients whose
sputum smears remain positive at the end of the two
month intensive phase of treatment an additional month of
intensive phase treatment is given followed by the continu-
ation phase. The outcomes of patients at the end of the six
months of treatment is recorded into one of the following
six mutually exclusive categories according to the recom-
mendations of the Union and Wold Health Organisation
[1,8] 1) cured: treatment completed with a negative sputum
smear in the last month of treatment and on at least one
previous occasion; 2) treatment completed: patient who has
completed treatment but does not meet the criteria to be
classified as a cure or failure; 3) treatment failure: patient
who is sputum smear positive at five months or later during
treatment; 4) died: patient who dies for any reason during
the course of treatment; 5) defaulted: patient whose treat-
ment is interrupted for two consecutive months or more;
6) transferred out: patient who has been transferred to an-
other recording and reporting unit and for whom treatment
outcome is unknown. Patients are considered as having
treatment success if they fall in categories (1) and (2).
Methods
A prospective cohort of all patients aged 15 years and
above, hospitalised in the service between October 2009
and May 2012 (32 months duration) with a first episode
of SPPTB and whose sputum smears remained positive
for AFB at the end of the two month intensive phase of
treatment was studied. After obtaining informed consent,
each patient’s medical records were reviewed. The follow-
ing baseline information on admission was extracted from
each patient’s file: age, sex, duration of illness before ad-
mission, clinical signs, alcohol and tobacco use, body mass
index, HIV serostatus as well as the CD4 cell count for
those with HIV infection. The result of the sputum smear
of each patient with a higher bacillary load of the two ex-
amined for diagnosis as well as that of the sputum smear
examined at the end of the two month intensive phase of
treatment were also recorded. Bacillary load was measured
by the semi-quantitative method in use in tuberculosis
control programmes (i.e. 1+, 2+, 3+) [8]. An admission
chest X-ray for each patient was reviewed and interpreted.
Each chest radiograph was divided into six zones by eye
and the presence or absence of parenchymal disease was
recorded for each zone. The presence or absence of cav-
ities was also noted.
A sputum sample was collected from each patient with
persistent positive sputum smears after two months of
treatment for culture and drug susceptibility testing to the
different antituberculosis drugs. Cultures forM. tuberculosis
were carried out using the classical Lowenstein-Jensen (LJ)
solid medium and susceptibility to different antituberculosis
drugs (rifampicin, isoniazid, ethambutol and streptomycin)
was based on the standard proportion method. Sputum
specimens collected from each eligible patient were decon-
taminated and inoculated onto LJ. Cultures were incubated
at 37°C and read weekly for growth for a maximum dur-
ation of 8 weeks. The identification of the cultured strains
was based on the following: culture aspects on the two
media, resistance to thiophene-2-carboxylic acid hydrazide
(TCH, 2 mg/l), susceptibility to para-amino-salicylic acid
(PAS, 0.5 mg/l), reduction of nitrates, niacin production
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and catalase production at 22°C and 68°C. Drug suscep-
tibility testing of M. tuberculosis complex strains iso-
lated from cultures was performed using the indirect
proportion method on LJ medium as described by Canetti
et al. [9]. A patient was considered to harbour drug-
resistant M. tuberculosis if the number of colonies grow-
ing on a medium containing 0.2 mg/l INH, 2 mg/l EMB,
4 mg/l SM or 40 mg/l RMP exceeded 1% of the growth on
a drug-free culture plate.
All the patients with positive sputum smears at the end
of the initial intensive phase of treatment were given an
additional month of intensive phase therapy followed by a
three month continuation phase of treatment. Sputum
smears of each patient were again examined for AFB at
the end of the fifth and sixth month of treatment. Out-
comes of treatment were then recorded accordingly at the
end of six months of therapy. The study was approved by
the administrative authorities of the YJH and Cameroon
National Ethics Committee.
Statistical analysis
Data were analysed with the use of the SPSS® statistical
software version 17 (SPSS Inc., Chicago, USA). Chi square
and Fisher’s exact tests were used to compare proportions,
and Mann–Whitney U test was used to compare quantita-
tive variables in both groups. Logistic regression analysis
was used to determine the baseline factors associated with
culture non-conversion at the end of the second month of
intensive phase of antituberculosis therapy. Potential
candidate predictors were first investigated in univariate
analysis and significant variables (based on a threshold
probability of 0.1) were all entered in the same multivar-
iable logistic model to determine independent predictors
for culture non-conversion in patients with persistent spu-
tum smear positivity after two months of intensive therapy.
A p-value <0.05 was used to characterize significant results.
Results
Study population
A total of 953 patients with SPPTB were admitted in the
service over the study period. Ninety-seven (10.2%) of
these patients presented persistent sputum smear positivity
at the end of the two month intensive phase of antituber-
culosis therapy. Nine of the 97 patients did not have a spu-
tum culture for M. tuberculosis and two patients’ cultures
yielded atypical mycobacteria. They were therefore ex-
cluded from further analysis. Of the 86 patients analysed,
63 (73.3%) were men and their median (25th – 75th percen-
tiles) age was 33 (26–42) years (Table 1). Forty-six (53.5%)
of the 86 patients had positive culture for M. tuberculosis.
Clinical and radiological profiles
Table 1 compares the clinical and radiological character-
istics of patients with positive sputum smears at the end
of the two month intensive phase of treatment by culture
status for M. tuberculosis. The duration of symptoms prior
to starting treatment was similar between patients with
positive culture (C+) and negative cultures for M. tubercu-
losis (C–). The prevalence of selected characteristics of cul-
ture positive patients (C+ ) as compared to culture negative
patients (C–) were 23.9% vs 32.5% (p = 0.376) for HIV in-
fection, 13% vs. 32.5% (p = 0.03) for haemoptysis and 67.4%
vs. 72.5% (p = 0.607) for cavitation on chest X-ray. In a mul-
tivariable logistic regression model, the absence of haemop-
tysis [odd ratio 4.65 (95% confidence interval: 1.14-18.95)]
and current smoking [7.26 (1.59-33.23)] were the main de-
terminants of non-conversion of sputum culture after two
months of intensive treatment.
Bacteriological profile
The bacteriological profile of patients is described in
Table 2. The prevalence of high bacillary load (3+) at
baseline and after two months of intensive treatment
was similar in the two groups of patients. Of the 46C +
patients, 5 (10.9%) were resistant to isoniazid, 2 (4.3%)
were resistant to rifampicin and 2 (4.3%) had multiresis-
tant strains of M. tuberculosis.
Outcomes
There was a trend toward lower therapeutic success among
C + patients compared with C– ones, although the differ-
ence did not reach statistical significance (64.1% vs. 79.5%,
p = 0.131). There was a significantly high treatment failure
rate among C + patients as compared to C– patients
(28.2% vs. 7.7%, p = 0.023; Table 3). The sensitivity and spe-
cificity were 78.6% and 55.4% for culture non-conversion
after intensive treatment phase, in predicting anti-TB treat-
ment failure. Of the five patients for whom the involved
M. tuberculosis strain was resistant to at least one of the
drugs of the category I regimen, 3 (60%) had treatment
failure against 8 (19.5%) among those with non-resistant
mycobacterium strains (p = 0.080). The two patients with
multiresistant strains had treatment failure.
Discussion
Four main findings emerge from this study conducted in a
country with medium endemicity for tuberculosis among
patients with positive smear after the intensive phase of
treatment for a first episode of SPPTB: 1) over half of the
patients with positive smears after the intensive phase of
treatment have positive cultures for M. tuberculosis (cul-
ture non-conversion); 2) current active smoking and ab-
sence of haemoptysis are the main determinants of culture
non-conversion; 3) about 4% of patients with culture non-
conversion have multidrug resistant TB; and 4) treatment
failure is very high among patients with positive cultures
compared to those with negative cultures.
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Our findings suggest that over half of the patients with
persistent positive smears on direct examination after
the intensive phase of anti-TB treatment also have posi-
tive cultures, and therefore remain contagious. In a co-
hort followed by Su and co-workers [7], Involving 113
patients with positive smears after receiving intensive
treatment, 56% also had positive cultures for M. tubercu-
losis. Our findings are also similar to those reported by
Ramarokoto et al. in Madagascar [10]. WHO guidelines
are currently against extending the intensive phase of
treatment among patients who remain smear positive
after two months of an intensive treatment with a regimen
containing rifampicin [3]. This recommendation essen-
tially is based on the fact that positive sputum smears on
direct examination following the intensive phase of anti-
TB treatment is not a good indicator of the treatment
outcome. It is instead recommended that sputum cul-
ture and drug susceptibility tests be conducted in all pa-
tients with positive smears at the completion of the
intensive treatment and at the end of the 3rd month of
treatment. In resource limited countries however, the high
incidence of tuberculosis and insufficient equipment re-
main deterrents to systematic sputum culture and suscep-
tibility tests.
Table 1 Clinical and radiological characteristics of patients with positive sputum smear at the end of the second
month of intensive treatment, with positive (C+) or negative (C–) culture for Mycobacterium tuberculosis
Characteristics Overall (n = 86) C + (n = 46) C– (n = 40) p
Sex
Men, n (%) 63 (73.3) 35 (76.1) 28 (70) 0.525
Women, n (%) 23 (26.7) 11 (23.9) 12 (30)
Median age, years (25th-75th percentiles) 33 (26–42) 35.5 (25.8-46.5) 33 (26.3-38.8) 0.259
Age groups, years, n (%)
< 33 40 (46.5) 22 (47.8) 18 (45.0) reference
33-42 26 (30.2) 9 (19.6) 17 (42.5) 0.105
> 42 20 (23.3) 15 (32.6) 5 (12.5) 0.133
Clinical signs
Haemoptysis, n (%) 19 (22.1) 6 (13) 13 (32.5) 0.030
Dyspnoea, n (%) 24 (27.9) 11 (23.9) 13 (32.5) 0.375
Fever, n (%) 74 (86) 41 (89.1) 33 (82.5) 0.376
Weight loss, n (%) 80 (93) 43 (93.5) 37 (92.5) 0.859
Median BMI, kg/m2 (25th-75th percentiles) 19.3 (17.4-20.8) 18.9 (17.2-21.0) 19.4 (17.5-20.3) 0.698
BMI strata, kg/m2
< 18.5 18 (20.9) 11 (23.9) 7 (17.5) 0.466
≥ 18.5 35 (76.1) 35 (76.1) 33 (82.5)
BCG vaccination, n (%) 63 (73.3) 33 (71.7) 30 (75.0) 0.733
Diabetes mellitus, n (%) 2 (2.3) 2 (4.3) 0 (0) 0.182
Habits
Smoking, n (%) 22 (25.6) 17 (37) 5 (12.5) 0.010
Alcohol consumption, n (%) 22 (25.6) 13 (28.3) 9 (22.5) 0.541
Median symptoms duration, weeks (25th-75th percentiles) 13 (8–20.3) 12 (6–21) 13 (8–20) 0.744
HIV Positive, n (%) 24 (27.9) 11 (23.9) 13 (32.5) 0.376
Median CD4, /mm3 (25th-75th percentiles) 187 (151.3-216.3) 187 (151–240) 187 (144–210) 0.697
CD4 strata, /mm3
< 50 3/24 (12.5) 1/11 (9.1) 2/13 (15.4) 1.000
50-200 15/24 (62.5) 7/11 (63.6) 8/13 (61.5) 1.000
> 200 6/24 (25.0) 3/11 (27.3) 3/13 (23.1) Reference
Chest X-ray
Number of affected areas > 4, n (%) 46 (53.5) 28 (60.9) 18 (45.0) 0.141
Presence of cavitations, n (%) 60 (69.8) 31 (67.4) 29 (72.5) 0.607
C+, positive culture for Mycobacterium tuberculosis; C– , negative culture for Mycobacterium tuberculosis; BMI, body mass index.
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In Cameroon where about 6-13% of patients with smear
positive tuberculosis are still positive after completing the
intensive phase of treatment [6,11], our findings suggest
that per year, about 1200 patients with tuberculosis in the
country remain contagious after completing this phase of
treatment. The current approach of the National Tuber-
culosis Control Program(NTCP), which consists in ex-
tending this phase by an additional month [2] needs to be
clarified by further studies, since despite the extension of
the intensive phase, the failure rate is fairly high especially
in the subgroup of patients with positive culture. Such a
strategy could aid in reducing the spread of the disease by
a number of these patients. It is however known that the
median time from treatment start to achieving negative
smear is about 17.5 days [8]. Therefore, patients with per-
sistent positive smears after two months of intensive treat-
ment are likely a subgroup of patients for whom specific
actions are needed to optimise the treatment and care.
The adoption therefore in developing countries of modern
rapid methods for identifying and testing the susceptibility
of M. tuberculosis to at least rifampicin should be con-
sidered and encouraged. These will help considerably in
improving clinical decision making. Even in the absence
of multiple drugs resistant tuberculosis, treatment failure
was high in group C + patients. These were essentially clin-
ical failure, likely due to poor adherence; suggesting the
need for an ongoing supervision of these patients through-
out the entire course of their treatment.
None of the baseline radiographic or bacteriologic
features was associated with culture non-conversion
after intensive treatment among our patients. A study
in Taiwan reported the presence of cavitation or con-
densation on chest X-ray, as well as non-use of Direct
Observed Treatment strategy, to be associated with cul-
ture non-conversion [7]. Elsewhere, high baseline bacillary
load (≥2+) has been associated with delayed culture con-
version [4]. In this study, haemoptysis was observed to be
significantly associated with patients having culture con-
versions (C+). The exact reason for this association is not
known. In agreement with the results of our study, current
smoking at baseline has also been observed to be associ-
ated with culture non-conversion in similar studies from
Brazil [12] and Spain [13]. It could be speculated that the
impairment of local pulmonary defences caused by the
persistent irritation of tobacco smoke may play a role.
Screening for these factors in settings where culture of
mycobacterium are not available, could aid the identifica-
tion of a subgroup of patients who require more intensive
monitoring.
In this study, the prevalence of multidrug resistant M.
tuberculosis strains in patients with positive cultures was
4.3%. This prevalence is relatively high as compared to
rates (0 to 2.7%) reported for patients with a first epi-
sode of SPPTB in the same region [14]. This suggests
that patients with persistent culture positivity at the end
of the 2 month intensive phase of anti-tuberculosis treat-
ment constitute a high risk group for multidrug resistant
tuberculosis MDR-TB. As such this group of patients
should like retreatment cases be included in the high risk
group of patients for MDR-TB so that they could benefit
from sputum cultures for identification and drug suscepti-
bility testing of their M. tuberculosis strains. This will
allow for a timely adjustment of their treatment as op-
posed to waiting until 3 months as recommended pres-
ently by WHO [3]. Cost-effectiveness studies are needed
to guide the choice of the appropriate strategies particu-
larly in resources-limited settings.
Table 2 Bacteriological profile of patients with positive sputum smear at the end of the second month of intensive
treatment, with positive (C+) or negative (C–) culture for Mycobacterium tuberculosis
Characteristics Overall (n = 86) C + (n = 46)* C– (n = 40)* p
Initial bacillary load > 2+ 69 (80.2) 37 (80.4) 32 (80.0) 0.959
Bacillary load at 2-month of treatment > 2+ 12 (14.0) 7 (15.2) 5 (12.5) 0.717
Multidrug resistant strain / 2 (4.3) / /
Resistance to rifampicin / 2 (4.3) / /
Resistance to isoniazid / 5 (10.9) / /
Resistance to ethambutol / 1 (2.3) / /
Resistance to streptomycin / 5 (10.9) / /
Resistance to at least one anti-tuberculosis drugs 7 (15.2) / /
*7C + patients and 1C- patient were transferred to another centre.
Table 3 Outcome of patients with positive sputum smear
at the end of the second month of intensive treatment,
with positive (C+) or negative (C–) culture for
Mycobacterium tuberculosis
Outcome* Overall (n = 78) C + (n = 39) C– (n = 39) p
Therapeutic success 56 (71.8) 25 (64.1) 31 (79.5) 0.131
Failure 14 (17.9) 11 (28.2) 3 (7.7) 0.023
Loss to follow-up 7 (9.0) 3 (7.7) 4 (10.3) 1.000
Deceased 1 (1.3) 0 (0) 1 (2.6) 1.000
* 7C + patients and 1C- patient were transferred to another centre.
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The present study has some limitations. No sputum
smear control examination was done at the end of the
extended intensive phase. This would have allowed us to
assess the effects of non-conversion after 3 months of
intensive treatment on the outcomes of care. Further-
more, no culture was performed at the end of the entire
treatment cycle, and the outcome of care was essentially
guided by the WHO recommendations, based on smear
examination at five or six months of treatment [2,3]. The
study also has some major advantages including its pro-
spective nature, the enrolment of both HIV + and HIV-
patients, and the relatively large number of patients with
persistent positive smears after receiving intensive phase
treatment.
Conclusions
Over half of the patients with a first episode of SPPTB
presenting persistent positive smears after an intensive
phase of anti-TB treatment have positive cultures for
Mycobacterium tuberculosis in Yaounde. Treatment fail-
ure is more frequent among these patients, even in the
absence of MDR-TB. Our findings support the need for
a monitoring of the entire treatment cycle in these pa-
tients, and the adoption of rapid drug susceptibility tests
for patients with persistent positive smears after inten-
sive phase treatment. This will allow timely adjustment
of the treatment as opposed to waiting until the end of
the third month of treatment as currently done.
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